Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
about
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in childrenSocial, economic, and health impact of the respiratory syncytial virus: a systematic searchApproved Antiviral Drugs over the Past 50 YearsA cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set.Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab ProphylaxisProspective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study.Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study.Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infectionAntiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate ModelPre-exposure Prophylaxis With OspA-Specific Human Monoclonal Antibodies Protects Mice Against Tick Transmission of Lyme Disease Spirochetes.Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection.A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom.Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).Recent developments with live-attenuated recombinant paramyxovirus vaccines.Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals.Prematurity and the burden of influenza and respiratory syncytial virus disease.Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Human Metapneumovirus Infection is Associated with Severe Respiratory Disease in Preschool Children with History of Prematurity.RSV: Immunoprophylaxis and non-invasive respiratory support in ex-preterms: A northern UK perspective.Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study 1.Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
P2860
Q24197915-3D335B2B-67F9-4C61-90D6-978BA6FC82DBQ26852865-1602AC38-1861-4D77-9F0C-016861AF745EQ27755387-2521A2A9-9FE9-4464-A437-D2483F047AD4Q30882668-F488D415-B4CD-461E-8E1B-8623A50A6CB3Q34049590-555CB39B-7811-45C6-90F0-870B6A044A12Q34648807-A54933CD-BD7D-4C93-B677-F502E65AF4AFQ35106819-BD92073E-D2BB-45B9-B17A-46CD26F9AEB7Q35160026-538AC049-9936-4BF1-865A-E004ABC2BA31Q35641632-DC1D9C34-8647-4145-9A32-47C9FD3BC1C9Q37033087-FEF466BD-97BC-4E66-A7A5-5905AF2BE483Q37067663-DA9E4E11-C1EF-47B9-8E89-4E9D7D2A7A96Q37075484-104EF11B-B0E9-48CC-9F45-395DC7B69D9AQ37484236-1C98956A-4335-4F46-817B-BEFC6DF033C2Q37660572-0790B35F-C59D-49A6-BC5E-AB3C396A4472Q38008607-93A045B3-D316-4C9B-BAC6-AD49CB1AD7A0Q38182054-990D2D6F-0B03-44C2-8775-6EB5217652CCQ38637989-D7DAAFA1-B1EF-4074-95B5-1EC869AA5698Q38671952-7A5122A8-5B0C-40E3-B361-73746EEB3D24Q40790465-0782FE38-47F4-4535-AA5D-FE51D5EDCE78Q41664303-3AB13C83-8537-4037-A620-43E0714D81CBQ45324366-F2E98160-76B0-4041-AFD1-223AB94FDB9CQ47112273-70C87BD1-FA87-4A16-BE67-02B0C9A0E286Q47132154-B2F9E4E8-3E81-4EE6-8D9E-C392B8D5DCDCQ50262223-5EB81BCF-9380-4D2C-8162-ADA9DD2FB966Q57570436-CB6893B9-1FB5-4009-92EC-8CD315E69B09
P2860
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Palivizumab for immunoprophyla ...... odelling of subgroup analyses.
@ast
Palivizumab for immunoprophyla ...... odelling of subgroup analyses.
@en
type
label
Palivizumab for immunoprophyla ...... odelling of subgroup analyses.
@ast
Palivizumab for immunoprophyla ...... odelling of subgroup analyses.
@en
prefLabel
Palivizumab for immunoprophyla ...... odelling of subgroup analyses.
@ast
Palivizumab for immunoprophyla ...... odelling of subgroup analyses.
@en
P356
P1476
Palivizumab for immunoprophyla ...... modelling of subgroup analyses
@en
P304
iii-iv, 1-124
P356
10.3310/HTA15050
P50
P577
2011-01-01T00:00:00Z